Clinical Trial Update: Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update on enteric-coated mycophenolate sodium (Myfortic) in heart transplant recipients with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Symptoms
• Heart Transplantation

Drugs mentioned

• Mycophenolate sodium (Enteric-coated, Myfortic) (mycophenolate mofetil (enteric-coated formulation))

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Gastrointestinal Symptoms, Heart Transplantation | Phase 4 | Status: COMPLETED | Results posted: 2020-07-08